Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Debt: 2019-2025

Historic Total Debt for China SXT Pharmaceuticals (SXTC) over the last 7 years, with Mar 2025 value amounting to $798,448.

  • China SXT Pharmaceuticals' Total Debt fell 98.64% to $102,601 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year decrease of 8.19%. This contributed to the annual value of $798,448 for FY2025, which is 30.85% up from last year.
  • As of FY2025, China SXT Pharmaceuticals' Total Debt stood at $798,448, which was up 30.85% from $610,183 recorded in FY2024.
  • China SXT Pharmaceuticals' Total Debt's 5-year high stood at $12.2 million during FY2021, with a 5-year trough of $11,404 in FY2022.
  • Its 3-year average for Total Debt is $564,649, with a median of $610,183 in 2024.
  • In the last 5 years, China SXT Pharmaceuticals' Total Debt tumbled by 99.91% in 2022 and then soared by 2,401.89% in 2023.
  • China SXT Pharmaceuticals' Total Debt (MRY) stood at $12.2 million in 2021, then plummeted by 99.91% to $11,404 in 2022, then soared by 2,401.89% to $285,315 in 2023, then soared by 113.86% to $610,183 in 2024, then surged by 30.85% to $798,448 in 2025.
  • Its Total Debt was $798,448 in FY2025, compared to $610,183 in FY2024 and $285,315 in FY2023.